🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

David A. Liebner

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ORCID: 0000-0002-7657-4137

Also affiliated with The Ohio State University Wexner Medical Center, The Ohio State University

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.618Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009472
Top 32%
0.618DataRank
Top 32%16 citations

James L. Chen, Austin C Goodrich, Brian A. Van Tine, Jordan D. Campbell, Allison L. Richards +9 more

Papers

Driven by 7 papers — median percentile 68. Top paper: “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial”.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02128-z
N/A
5.6DataRank · unranked
197 citations

Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski +39 more

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009472
Top 32%
0.618DataRank
Top 32%16 citations

James L. Chen, Austin C Goodrich, Brian A. Van Tine, Jordan D. Campbell, Allison L. Richards +9 more

A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11511
N/A
0DataRank · unranked
50 citations

Michelle R. Mahoney, Suzanne George, Cristina R. Antonescu, David A. Liebner, Brian Andrew Van Tine +6 more

Clinical markers of immunotherapy outcomes in advanced sarcoma

BMC Cancer(2023)10.1186/s12885-023-10758-w
N/A
0DataRank · unranked
4 citations

Dionisia Quiroga, Han Gil Kim, Scott Lenobel, Menglin Xu, Hans Iwenofu +5 more

Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas

Cancers(2024)10.3390/cancers16101918
N/A
0DataRank · unranked
3 citations

Han Gil Kim, Menglin Xu, Tyler Roach, David A. Liebner, David J. Konieczkowski +2 more

Emerging Trends in Immunotherapy for Adult Sarcomas

The Oncologist(2023)10.1093/oncolo/oyad052
N/A
0DataRank · unranked
6 citations

Luxi Chen, David A. Liebner, Joal D. Beane, Mark P. Rubinstein, Raphael E. Pollock +3 more

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.11562
N/A
0DataRank · unranked
7 citations

Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark A. Dickson, Richard F. Riedel +10 more